| GRAIL INC. DL-,01 |
| USA |
| Gesundheit |
| US3847471014 / A40F8M |
| NL0 (Frankfurt) / GRAL (NASDAQ) |
| FRA:NL0, ETR:NL0, NL0:GR, NASDAQ:GRAL |
| - |
| https://grail.com/ |
|
GRAIL, Inc. is a healthcare biotechnology company focused on early cancer detection. The company develops and commercializes blood-based screening products designed to identify signals from multiple cancer types before symptoms appear, supporting ear..
>Volltext.. |
| 2517.13 Mio. EUR |
| 1849.77 Mio. EUR |
| 137.14 Mio. EUR |
| -317.61 Mio. EUR |
| -347.26 Mio. EUR |
| -9.11 EUR |
| 44.83 Mio. EUR |
| 60.91 Mio. EUR |
| -255.6 Mio. EUR |
| 11.02 |
| 11.84% |
| 80.66% |
| - |
| - |
| - |
| - |
| GRAIL INC, GRAIL INCORPORATED, NASDAQ:GRAL |
| 29.07.26 |
|
||||
|
||||
|